Immunogen | IMGN - Frais De Vente Et D'Administration



Frais De Vente Et D'Administration Changement Date
AbbVie USD 3.89B 325M 2025-12
Agios Pharmaceuticals USD 42.97M 1.7M 2025-12
Amgen USD 1.94B 237M 2025-12
Astellas Pharma JPY 221.78B 14.94B 2025-12
AstraZeneca USD 4.61B 4.46B 2025-12
Bristol-Myers Squibb USD 2.18B 392M 2025-12
Eli Lilly USD 3.13B 391.3M 2025-12
Emergent BioSolutions USD 182.8M 82.3M 2023-06
Exelixis USD 123.02M 19.9M 2025-12
Halozyme Therapeutics USD 64.64M 27.11M 2025-12
Heron Therapeutics USD 23.74M 605K 2025-12
Intrexon USD 10.31M 41K 2024-06
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
MacroGenics USD 7.94M 1.96M 2025-12
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Novartis USD 3.44B 132M 2025-12
Pfizer USD 4.08B 894M 2025-12
Regeneron Pharmaceuticals USD 775M 117.2M 2025-12
Roche Holding CHF 7.28B 3.99B 2025-12
Sanofi EUR 2.75B 455M 2025-12